Phaarmasia Limited has officially notified the stock exchange about the relocation of its registered office within Hyderabad's local limits. The pharmaceutical company has moved its registered office from its previous location to a new address within the same industrial area, maintaining its operational base in Telangana.

Office Relocation Details

The company has shifted its registered office within the IDA Jeedimetla area of Hyderabad. This internal move keeps the company within the same city limits while potentially providing enhanced operational capabilities.

Regulatory Compliance

Phaarmasia Limited has fulfilled its disclosure obligations by informing BSE Limited about this corporate change. The notification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which mandates listed companies to disclose material events and corporate actions.

Company Secretary and Compliance Officer Urvashi Bhatia, with membership number ACS 46877, signed the official communication to the exchange. The company's scrip code 523620 on BSE remains unchanged following this relocation.

Corporate Information

Phaarmasia Limited, incorporated in 1981 with CIN L24239TG1981PLC002915, continues its operations from the Hyderabad base. The company maintains its contact information and business operations while transitioning to the new registered office address within the same industrial development area.

Phaarmasia Limited , a pharmaceutical company based in Hyderabad, has taken a significant step towards restructuring its assets. The company's Board of Directors has approved the sale of land and building located at Plot Nos. 16A and 16B, Phase III, IDA Jeedimetla, Hyderabad, following shareholder approval obtained through a postal ballot.

Key Developments

1. Shareholder Approval: The company conducted a postal ballot to seek shareholder consent for the sale of the property. The resolution was passed with a substantial majority, demonstrating strong shareholder support for the decision.

2. Board Meeting Details: The board meeting was held on October 13, through audio-video means, highlighting the company's adoption of modern communication technologies for corporate governance.

3. Authorization for Sale Agreement: The Board has authorized Mr. Naga Bhaskarrao Yallapragada, Whole-time Director, and Mr. Nev Prasada Rao, Chief Financial Officer, to execute the sale agreement and related documents on behalf of the company.

4. Execution of Sale Deed: Mr. Maneesh Sapte, Director, has been authorized to execute and register the sale deed before the Sub-Registrar, ensuring proper legal compliance in the property transaction.

Voting Results

The company provided detailed voting results for the resolution to approve the sale of land and building:

The voting results indicate overwhelming support for the resolution, with 99.23% of the total votes cast in favor of the property sale.

Implications

This decision to sell the Hyderabad property, which constitutes a substantial undertaking of the company, could have significant implications for Phaarmasia Limited's financial structure and future operations. While the specific reasons for the sale have not been disclosed, such moves are often associated with efforts to optimize asset utilization, reduce debt, or reallocate resources for strategic initiatives.

Investors and stakeholders will likely be watching closely to see how Phaarmasia Limited utilizes the proceeds from this sale and what impact it may have on the company's future performance and strategic direction in the pharmaceutical sector.

As the pharmaceutical industry continues to evolve, companies like Phaarmasia Limited must make strategic decisions to remain competitive and create value for shareholders. This property sale appears to be a step in that direction, backed by strong shareholder support.